Fitness

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year –…

1 year ago

SOLE FITNESS ANNOUNCES NEW DIRECTION IN LEADERSHIP AND VIRTUAL FITNESS OFFERINGS

Sole Fitness, an innovative leader in premium, affordable home fitness equipment, expands with new CEO, Brad White and development of…

1 year ago

GYMGUYZ Introduces GG DRIVE Platform, Boosting Franchisee Support and Growth

Personal training franchise paves the way for a new era of innovation and expansionLaunches the GG DRIVE platform, offering actionable,…

1 year ago

NeuFit Announces Expansion with New Centers of Excellence Across the Nation

Revolutionizing Rehabilitation and Performance Optimization through NeuFit's Innovative Neurological Approach AUSTIN, Texas, Sept. 17, 2024 /PRNewswire/ -- NeuFit, the leader in…

1 year ago

Altus Nova Technologies Completes Custom Software Project for Neufit, Revolutionizing Remote Physical Therapy in HealthTech and IoT

AUSTIN, Texas, Sept. 17, 2024 /PRNewswire/ -- Altus Nova Technologies, a leading digital product strategy, management, and development company based in…

1 year ago

MX3 DIAGNOSTICS LAUNCHES HEAT STRESS MANAGEMENT TOOLKIT

New feature set helps organizations combat heat-related stress with real-time monitoring and risk mitigation. AUSTIN, Texas and MELBOURNE, Australia, Sept. 16,…

1 year ago

Crunch Franchise Brings State-of-the-Art Fitness Facility to Port Arthur, TX

PORT ARTHUR, Texas, Sept. 16, 2024 /PRNewswire/ -- Crunch Franchise today announces the opening of Crunch Port Arthur in Port…

1 year ago

Healthy Habits in 30 Days: Life Time Launching New Complimentary “30 Strong Challenge” Available to All; Registration open for Oct. 2 start

New program emphasizes range of habits: 30 grams of protein per meal, daily movement, eliminating alcohol and more CHANHASSEN, Minn.,…

1 year ago

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically…

1 year ago